On Thursday, Elanco Animal Health shares climbed by the most intraday since May, after the animal health firm boosted its adjusted profit and revenue guidance for the full year, following better-than-expected second-quarter results. Bloomberg Intelligence sees the launches of dog medications Credelio Quattro and Zenrelia bolstering Elanco's broader portfolio, with a big portion of new customers buying multiple products.

Jeff Simmons, Elanco's President and CEO, breaks down the firm's strategic framework and explains why he sees sustainable value creation continuing for years to come. Jeff speaks with Carol Massar and Norah Mulinda on Bloomberg Businessweek Daily.